logo
athenahealth, Humana, and Your Health Closing Critical Gaps at the Point of Care While Reducing Administrative Burden on Clinicians

athenahealth, Humana, and Your Health Closing Critical Gaps at the Point of Care While Reducing Administrative Burden on Clinicians

Business Wire2 days ago

BOSTON--(BUSINESS WIRE)--athenahealth, a leading provider of network-enabled software and services for healthcare practices nationwide, in collaboration with key partners Humana (NYSE: HUM) and Your Health, a South Carolina-based primary care practice, have received a 2025 Points of Light Award from KLAS. This recognition is for the case study, ' Closing Care Gaps & Reducing the Administrative Burden Through Improved Data Sharing.' This recognition highlights how integrating timely and relevant information directly into the clinical workflow can help improve health outcomes for patients.
"Facilitating collaboration between payer and provider organizations to improve care and eliminate administrative tasks is how we can deliver care experience that patients expect and deserve,' said Sam Lambson, VP of Product Management, Data and Ecosystem.
'At Your Health, our clinicians focus on delivering care that's preventative, personalized, and high-quality. This requires our staff to track patients and their health beyond the clinic and identify and address care gaps before they escalate to more serious or costly conditions,' said Will Stillinger, chief operating officer, Your Health. 'Humana and athenahealth have established an open and seamless information exchange that helps us deliver better care while eliminating administrative burden and costly interventions. We are excited by the opportunity for future care intervention pathways based on factors like Social Determinants of Health.'
To accomplish this real-time data exchange, Humana and athenahealth partnered to implement athenaPayer's Care and Diagnosis Gaps solutions to identify and surface care and diagnosis gaps among Humana's Medicare Advantage members. Utilizing athenahealth's cloud-based, single instance platform, Your Health clinicians can now see relevant patient information ahead of visits, address identified gaps during the visit, and document diagnoses and care plans directly within athenaOne. Leveraging Da Vinci APIs, athenahealth automatically sends validated data back to Humana to appropriately document and report on the quality of care they provide to members.
As the case study reports, athenahealth has uncovered an average of 4.8 additional care gaps and 4.7 additional diagnosis gaps per member among Humana's Medicare Advantage population, and Humana has been able to close 35% of its CMS Star gaps. Your Health clinicians now spend less time identifying care gaps with limited information, improving care while reducing documentation time.
'By investing in improving preventive care and management of chronic conditions, we're able to help our members stay healthier and out of the hospital. And that leads to lower costs for members themselves,' said Chris Walker, associate vice president of Enterprise Transformation and Interoperability, Humana. 'This partnership – and the positive results we've collectively achieved – is another example of how we are working together to improve patient care and deliver better health outcomes.'
athenahealth continues to expand its work with payer organizations, boosting information sharing across its network of more than 160,000 providers and facilitating new pathways to improve patient outcomes. To date, athenahealth has surfaced information on more than 25 million care and diagnosis gaps across commercial, Medicare, Medicaid, and ACA lines of business. The company has additional solutions that support provider and payer collaboration, including electronic prior authorization, transition of care, and referral management capabilities.
'We are working to create a thriving healthcare ecosystem that delivers accessible, high-quality, and sustainable care for all,' said Sam Lambson, vice president of Product Management, Data and Ecosystem Platform for athenahealth. 'Our work with Humana and Your Health is an example of exactly what that ecosystem can look like when practices are equipped with purpose-built, innovative solutions that ease clinician burden and enhance patient outcomes. Facilitating collaboration between payer and provider organizations to improve care and eliminate administrative tasks is how we can deliver care experience that patients expect and deserve.'
The KLAS Points of Light annual awards celebrate success stories achieved by payers, healthcare organizations, and healthcare IT companies who have partnered to reduce costs and inefficiencies and improve patient experience. The organizations are honored by the recognition and recently presented about their collaboration at the KLAS K2 Collaborative Summit, May 20-22 in Salt Lake City, UT.
To learn more about the challenges, outcomes, and key lessons from this collaboration, please visit: https://www.athenahealth.com/KLAS-POL-2025.
About athenahealth, Inc.
athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. athenahealth partners with practices with purpose-built software backed by expertise to produce the insights needed to drive better clinical and financial outcomes. We're inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
About Your Health
Your Health is a leading healthcare organization and physician group committed to providing high-quality, patient-centered care across various specialties, including primary and specialty care for seniors in South Carolina, Georgia, and Florida. With 300 physicians, we deliver care in homes, local offices, facilities, and virtually, ensuring services are available wherever needed. Through continuous education and clinical excellence, Your Health aims to improve health outcomes and enhance community well-being. Our team collaborates closely with families and partners to provide coordinated, compassionate care that prioritizes patients. For more information, please visit www.yourhealth.org.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lilly's experimental obesity drug shows promise in early study
Lilly's experimental obesity drug shows promise in early study

Miami Herald

time3 hours ago

  • Miami Herald

Lilly's experimental obesity drug shows promise in early study

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week. "The data look particularly strong, and should push the program back into investor conversations," Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors. Lilly has shared few details about eloralintide before now, as it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting. The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose. The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market. In March, Roche Holding AG entered into a $5.3 billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies. AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy. Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss. The company is studying eloralintide alone and in combination with Zepbound - similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Yahoo

time5 hours ago

  • Yahoo

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to 're-establish public confidence in vaccine science,' claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP's founding charter. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Martin Kulldorff, a biostatistician and epidemiologist, was among eight individuals selected by Kennedy to join the Advisory Committee on Immunization Practices (ACIP). Kulldorff has been an outspoken critic of COVID-19 lockdowns and vaccine mandates. His appointment has also raised questions due to his paid involvement in litigation against a major vaccine manufacturer, according to Reuters. Citing court records, Reuters notes that Kulldorff served as an expert witness in lawsuits against Merck & Co Inc (NYSE:MRK) over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV). The plaintiff accused the pharmaceutical company of not properly disclosing the vaccine's risks. Gardasil was approved in the U.S. in 2006 after going through clinical trials to prove its safety and a deposition in October, Kulldorff acknowledged that he had been paid $400 an hour for his work on the case and had billed approximately $33,000 through September. He also received a $4,000 retainer in connection with the North Carolina lawsuit, which was part of a broader legal effort encompassing about 200 related cases. In March, a federal judge ruled in favor of Merck in that particular case. Kulldorff's paid role as a litigation consultant could conflict with ACIP's established rules. According to the committee's guidelines, members are prohibited from serving as paid expert witnesses or litigation consultants in cases involving vaccine manufacturers while actively serving on the panel. Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, and higher pricing and demand in the U.S. Excluding China, sales grew 14%, or 16%, excluding the impact of foreign exchange. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit originally appeared on Sign in to access your portfolio

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Yahoo

time5 hours ago

  • Yahoo

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to 're-establish public confidence in vaccine science,' claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP's founding charter. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Martin Kulldorff, a biostatistician and epidemiologist, was among eight individuals selected by Kennedy to join the Advisory Committee on Immunization Practices (ACIP). Kulldorff has been an outspoken critic of COVID-19 lockdowns and vaccine mandates. His appointment has also raised questions due to his paid involvement in litigation against a major vaccine manufacturer, according to Reuters. Citing court records, Reuters notes that Kulldorff served as an expert witness in lawsuits against Merck & Co Inc (NYSE:MRK) over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV). The plaintiff accused the pharmaceutical company of not properly disclosing the vaccine's risks. Gardasil was approved in the U.S. in 2006 after going through clinical trials to prove its safety and a deposition in October, Kulldorff acknowledged that he had been paid $400 an hour for his work on the case and had billed approximately $33,000 through September. He also received a $4,000 retainer in connection with the North Carolina lawsuit, which was part of a broader legal effort encompassing about 200 related cases. In March, a federal judge ruled in favor of Merck in that particular case. Kulldorff's paid role as a litigation consultant could conflict with ACIP's established rules. According to the committee's guidelines, members are prohibited from serving as paid expert witnesses or litigation consultants in cases involving vaccine manufacturers while actively serving on the panel. Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, and higher pricing and demand in the U.S. Excluding China, sales grew 14%, or 16%, excluding the impact of foreign exchange. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit originally appeared on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store